ABBV 4Q18 HCV sales=$862M—flat vs 3Q18; full-year 2018 HCV sales=$3.62B: https://news.abbvie.com/article_display.cfm?article_id=11771 4Q18 HCV sales were $408M (47%) US; $462M (53%) ex-US. Full-year 2018 HCV sales were $1.62B (45%) US; $2.00B (55%) ex-US.